A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
Latest Information Update: 05 Sep 2024
At a glance
- Drugs Remibrutinib (Primary) ; Charcoal; Colestyramine; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms REMODEL-1
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 13 Jan 2023 Planned End Date changed from 23 Nov 2029 to 30 Oct 2030.
- 13 Jan 2023 Planned primary completion date changed from 31 Oct 2025 to 30 Apr 2026.
- 28 Jun 2022 Results from two studies (REMODEL I/II) assessing efficacy, safety, and tolerability of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis presented at the 8th Congress of the European Academy of Neurology